10-Q: Gritstone Bio Reports Q2 2024 Results Amidst Financial Uncertainty
Quarterly Report
Gritstone Bio's Q2 2024 results reveal ongoing operating losses and a need for additional capital, raising concerns about the company's ability to continue as a going concern.
Summary
- Gritstone Bio reported a net loss of $23.4 million for the three months ended June 30, 2024, and a net loss of $63.8 million for the six months ended June 30, 2024.
- The company's cash used in operating activities was $60.4 million for the six months ended June 30, 2024.
- As of June 30, 2024, Gritstone had an accumulated deficit of $723.3 million and cash, cash equivalents, and marketable securities of $55.7 million.
- The company's current cash reserves are not sufficient to fund operations for the next 12 months, and they will need to raise additional capital.
- Gritstone intends to raise capital through equity offerings, debt financing, and potential collaborations, but there is no guarantee of success.
- Failure to secure additional funding could force the company to reduce operating expenses and delay or eliminate development programs.
- The company expects to be in default of its loan agreement's minimum liquidity requirement in the fourth quarter of 2024 if additional funds are not raised or terms are renegotiated.
- The company's existing cash is only sufficient to fund operations into the fourth quarter of 2024 if a default occurs.
Sentiment
Score: 3
Explanation: The document indicates significant financial challenges, including a going concern warning, high cash burn, and potential loan default. While there are some positive aspects, such as the recent public offering and progress in clinical programs, the overall sentiment is negative due to the company's financial instability.
Positives
- The company completed an underwritten public offering in April 2024, raising gross proceeds of $32.5 million.
- The company has a loan agreement with a potential borrowing capacity of $80 million, with $40 million drawn as of June 30, 2024.
- The company is progressing with its clinical programs, including GRANITE, SLATE, and CORAL.
Negatives
- The company's cash reserves are not sufficient to fund operations for the next 12 months.
- The company has incurred significant operating losses and has an accumulated deficit of $723.3 million.
- The company expects to be in default of its loan agreement's minimum liquidity requirement in the fourth quarter of 2024 if additional funds are not raised or terms are renegotiated.
- The company's existing cash is only sufficient to fund operations into the fourth quarter of 2024 if a default occurs.
- The company's research and development expenses remain high, at $53.9 million for the six months ended June 30, 2024.
- The company's marketable securities have decreased significantly, from $16.3 million to $4.8 million.
Risks
- The company's ability to continue as a going concern is subject to material uncertainty and dependent on its ability to obtain additional financing.
- Failure to secure additional funding could force the company to reduce operating expenses and delay or eliminate development programs.
- The company is subject to risks related to supply chain disruptions, inflation, market volatility, interest rate fluctuations, and recession risks.
- The company is dependent on third-party suppliers for key materials and services.
- The company is subject to broad market risks and uncertainties resulting from recent events, such as regional conflicts around the world.
- The company is subject to a minimum liquidity requirement under its loan agreement, which it may not be able to meet.
- The company is subject to a lawsuit alleging false and misleading statements concerning the status of the company's BARDA contract and its Phase 2b CORAL study.
Future Outlook
The company expects to incur significant expenses and increasing operating losses for at least the next several years as it continues its clinical development of, and seeks regulatory approval for, its product candidates. The company's cash, cash equivalents, and marketable securities are not sufficient to fund operations for the next 12 months, and they will need to raise additional capital. The company expects to be in default of its loan agreement's minimum liquidity requirement in the fourth quarter of 2024 if additional funds are not raised or terms are renegotiated.
Management Comments
- Management expects operating losses to continue for the foreseeable future.
- Management intends to raise additional capital through private and public equity offerings, debt financings, and potential future collaboration, license and development agreements.
- Management believes that government contract revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement.
Industry Context
The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Gritstone Bio's financial situation is not uncommon for a clinical-stage biotech company, but the need for additional capital and the potential loan default raise concerns about its long-term viability. The company's focus on personalized vaccines and self-amplifying mRNA technology aligns with current trends in the industry.
Comparison to Industry Standards
- Gritstone's cash burn rate of $60.4 million for the first six months of 2024 is relatively high for a company of its size, indicating a need for significant capital raises.
- Compared to other clinical-stage biotech companies, Gritstone's reliance on external funding and the uncertainty surrounding its BARDA contract are significant risks.
- Companies like Moderna and BioNTech, which have successfully commercialized mRNA vaccines, have significantly larger cash reserves and revenue streams, highlighting the challenges faced by companies like Gritstone.
- Gritstone's focus on personalized cancer vaccines and infectious disease programs is similar to other companies in the field, but its financial situation puts it at a disadvantage.
- The company's loan agreement and minimum liquidity requirements are common in the biotech industry, but the potential for default is a significant concern.
Legal Proceedings
- A putative class action complaint was filed against the company and certain of its officers alleging false and misleading statements concerning the status of the company's BARDA contract and its Phase 2b CORAL study.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential for dilution.
- Employees may be affected by potential workforce reductions or program delays.
- Customers and partners may be impacted by the company's ability to continue its development programs.
- Creditors face the risk of default on the company's loan agreement.
Next Steps
- The company intends to raise additional capital through private and public equity offerings, debt financings, and potential future collaboration, license and development agreements.
- The company expects to report mature PFS data and additional long-term ctDNA data from the ongoing Phase 2 GRANITE trial in the third quarter of 2024 and overall survival data in mid-2025.
- The company is working on implementing changes to address the FDA's concerns regarding the clinical hold on its Phase 2b CORAL clinical trial.
Key Dates
| Date | Description |
|---|---|
| 2015-08 | Gritstone bio, Inc. was incorporated in the state of Delaware. |
| 2017-03-24 | Date of the original Office Building Net Lease. |
| 2017-10-31 | Date of the Exclusive License Agreement with Arbutus Biopharma Corporation. |
| 2018-08 | Date of the Research Collaboration and License Agreement with bluebird bio, Inc. |
| 2019-01 | Date of the Emeryville Lease. |
| 2020-10 | Date of the Option and License and Development Agreement with Genevant Sciences GmbH. |
| 2020-12 | Date of the First PIPE Financing. |
| 2021-01 | Date of the Collaboration, Option and License Agreement with Gilead Sciences, Inc. |
| 2021-01 | Date of the Non-Exclusive License and Development Agreement with Genevant. |
| 2021-08-14 | Date of the CEPI Funding Agreement. |
| 2021-09 | Date of the Second PIPE Financing. |
| 2021-11 | Date of the Grant Agreement with the Gates Foundation. |
| 2022-03 | Date of the filing of the Registration Statement on Form S-3 with the SEC. |
| 2022-07-19 | Date of the Loan Agreement with Hercules Capital, Inc. and Silicon Valley Bank. |
| 2022-10 | Date of the Third PIPE Financing. |
| 2023-03-31 | Date of the First Amendment to Loan and Security Agreement. |
| 2023-09 | Date of the BARDA Contract. |
| 2024-02-29 | Date of the announcement of a reduction in workforce. |
| 2024-04-04 | Date of the underwritten public offering. |
| 2024-05-10 | Date of the Second Amendment to Office Building Net Lease. |
| 2024-06-17 | Date of the filing of a putative class action complaint. |
| 2024-06-30 | End of the quarterly period. |
| 2024-08-08 | Date of the share count. |
Keywords
biotechnology, vaccines, immunotherapy, clinical trials, oncology, infectious disease, mRNA, samRNA, capital raise, financial results, going concern, loan agreement, BARDA, COVID-19, HIV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.